406 related articles for article (PubMed ID: 22001562)
1. Effects of K201 on repolarization and arrhythmogenesis in anesthetized chronic atrioventricular block dogs susceptible to dofetilide-induced torsade de pointes.
Stams TR; Oros A; der Nagel Rv; Beekman JD; Chamberlin P; Dittrich HC; Vos MA
Eur J Pharmacol; 2011 Dec; 672(1-3):126-34. PubMed ID: 22001562
[TBL] [Abstract][Full Text] [Related]
2. Vernakalant is devoid of proarrhythmic effects in the complete AV block dog model.
Varkevisser R; van der Heyden MA; Tieland RG; Beekman JD; Vos MA
Eur J Pharmacol; 2013 Nov; 720(1-3):49-54. PubMed ID: 24211677
[TBL] [Abstract][Full Text] [Related]
3. Azimilide and dofetilide produce similar electrophysiological and proarrhythmic effects in a canine model of Torsade de Pointes arrhythmias.
Van Opstal JM; Leunissen JD; Wellens HJ; Vos MA
Eur J Pharmacol; 2001 Jan; 412(1):67-76. PubMed ID: 11166738
[TBL] [Abstract][Full Text] [Related]
4. Ventricular remodelling is a prerequisite for the induction of dofetilide-induced torsade de pointes arrhythmias in the anaesthetized, complete atrio-ventricular-block dog.
Dunnink A; van Opstal JM; Oosterhoff P; Winckels SK; Beekman JD; van der Nagel R; Cora Verduyn S; Vos MA
Europace; 2012 Mar; 14(3):431-6. PubMed ID: 21946817
[TBL] [Abstract][Full Text] [Related]
5. Atrial-specific drug AVE0118 is free of torsades de pointes in anesthetized dogs with chronic complete atrioventricular block.
Oros A; Volders PG; Beekman JD; van der Nagel T; Vos MA
Heart Rhythm; 2006 Nov; 3(11):1339-45. PubMed ID: 17074641
[TBL] [Abstract][Full Text] [Related]
6. Beat-to-Beat Variability in Preload Unmasks Latent Risk of Torsade de Pointes in Anesthetized Chronic Atrioventricular Block Dogs.
Stams TR; Oosterhoff P; Heijdel A; Dunnink A; Beekman JD; van der Nagel R; van Rijen HV; van der Heyden MA; Vos MA
Circ J; 2016 May; 80(6):1336-45. PubMed ID: 27151565
[TBL] [Abstract][Full Text] [Related]
7. Electrophysiological measurements that can explain and guide temporary accelerated pacing to avert (re)occurrence of torsade de pointes arrhythmias in the canine chronic atrioventricular block model.
Wijers SC; Bossu A; Dunnink A; Beekman JDM; Varkevisser R; Aranda Hernández A; Meine M; Vos MA
Heart Rhythm; 2017 May; 14(5):749-756. PubMed ID: 28213055
[TBL] [Abstract][Full Text] [Related]
8. LUF7244, an allosteric modulator/activator of K
Qile M; Beekman HDM; Sprenkeler DJ; Houtman MJC; van Ham WB; Stary-Weinzinger A; Beyl S; Hering S; van den Berg DJ; de Lange ECM; Heitman LH; IJzerman AP; Vos MA; van der Heyden MAG
Br J Pharmacol; 2019 Oct; 176(19):3871-3885. PubMed ID: 31339551
[TBL] [Abstract][Full Text] [Related]
9. The electromechanical window is no better than QT prolongation to assess risk of Torsade de Pointes in the complete atrioventricular block model in dogs.
Stams TR; Bourgonje VJ; Beekman HD; Schoenmakers M; van der Nagel R; Oosterhoff P; van Opstal JM; Vos MA
Br J Pharmacol; 2014 Feb; 171(3):714-22. PubMed ID: 24490860
[TBL] [Abstract][Full Text] [Related]
10. Beat-to-Beat variability of repolarization determines proarrhythmic outcome in dogs susceptible to drug-induced torsades de pointes.
Thomsen MB; Volders PG; Beekman JD; Matz J; Vos MA
J Am Coll Cardiol; 2006 Sep; 48(6):1268-76. PubMed ID: 16979017
[TBL] [Abstract][Full Text] [Related]
11. Reduced ventricular proarrhythmic potential of the novel combined ion-channel blocker AZD1305 versus dofetilide in dogs with remodeled hearts.
Johnson DM; de Jong MM; Crijns HJ; Carlsson LG; Volders PG
Circ Arrhythm Electrophysiol; 2012 Feb; 5(1):201-9. PubMed ID: 22080293
[TBL] [Abstract][Full Text] [Related]
12. An in vitro model for assessment of drug-induced torsade de pointes arrhythmia : effects of haloperidol and dofetilide on potential duration, repolarization inhomogeneities, and torsade de pointes arrhythmia.
Dhein S; Perlitz F; Mohr FW
Naunyn Schmiedebergs Arch Pharmacol; 2008 Dec; 378(6):631-44. PubMed ID: 18648775
[TBL] [Abstract][Full Text] [Related]
13. K201, a multi-channel blocker, inhibits clofilium-induced torsades de pointes and attenuates an increase in repolarization.
Hasumi H; Matsuda R; Shimamoto K; Hata Y; Kaneko N
Eur J Pharmacol; 2007 Jan; 555(1):54-60. PubMed ID: 17112502
[TBL] [Abstract][Full Text] [Related]
14. Electrophysiological mechanism of enhanced susceptibility of hypertrophied heart to acquired torsade de pointes arrhythmias: tridimensional mapping of activation and recovery patterns.
Kozhevnikov DO; Yamamoto K; Robotis D; Restivo M; El-Sherif N
Circulation; 2002 Mar; 105(9):1128-34. PubMed ID: 11877367
[TBL] [Abstract][Full Text] [Related]
15. A new method to calculate the beat-to-beat instability of QT duration in drug-induced long QT in anesthetized dogs.
van der Linde H; Van de Water A; Loots W; Van Deuren B; Lu HR; Van Ammel K; Peeters M; Gallacher DJ
J Pharmacol Toxicol Methods; 2005; 52(1):168-77. PubMed ID: 15935709
[TBL] [Abstract][Full Text] [Related]
16. Istaroxime, a positive inotropic agent devoid of proarrhythmic properties in sensitive chronic atrioventricular block dogs.
Bossu A; Kostense A; Beekman HDM; Houtman MJC; van der Heyden MAG; Vos MA
Pharmacol Res; 2018 Jul; 133():132-140. PubMed ID: 29753687
[TBL] [Abstract][Full Text] [Related]
17. Assessment of the proarrhythmic potential of the novel antiarrhythmic agent AZD7009 and dofetilide in experimental models of torsades de pointes.
Wu Y; Carlsson L; Liu T; Kowey PR; Yan GX
J Cardiovasc Electrophysiol; 2005 Aug; 16(8):898-904. PubMed ID: 16101634
[TBL] [Abstract][Full Text] [Related]
18. Torsade de pointes arrhythmias arise at the site of maximal heterogeneity of repolarization in the chronic complete atrioventricular block dog.
Dunnink A; Stams TRG; Bossu A; Meijborg VMF; Beekman JDM; Wijers SC; De Bakker JMT; Vos MA
Europace; 2017 May; 19(5):858-865. PubMed ID: 28525920
[TBL] [Abstract][Full Text] [Related]
19. Dofetilide induced torsade de pointes: mechanism, risk factors and management strategies.
Jaiswal A; Goldbarg S
Indian Heart J; 2014; 66(6):640-8. PubMed ID: 25634399
[TBL] [Abstract][Full Text] [Related]
20. Selective late sodium current inhibitor GS-458967 suppresses Torsades de Pointes by mostly affecting perpetuation but not initiation of the arrhythmia.
Bossu A; Houtman MJC; Meijborg VMF; Varkevisser R; Beekman HDM; Dunnink A; de Bakker JMT; Mollova N; Rajamani S; Belardinelli L; van der Heyden MAG; Vos MA
Br J Pharmacol; 2018 Jun; 175(12):2470-2482. PubMed ID: 29582428
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
